These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 27306791

  • 1. Molecular Pathways: Emergence of Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage Response and Repair Pathways in Cancer Cells.
    Rabalski AJ, Gyenis L, Litchfield DW.
    Clin Cancer Res; 2016 Jun 15; 22(12):2840-7. PubMed ID: 27306791
    [Abstract] [Full Text] [Related]

  • 2. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
    Perea SE, Baladrón I, Valenzuela C, Perera Y.
    Semin Oncol; 2018 Jan 15; 45(1-2):58-67. PubMed ID: 30318085
    [Abstract] [Full Text] [Related]

  • 3. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F, Huang X, Wu M, Gou S, Hu W.
    Cancer Lett; 2017 Jan 28; 385():168-178. PubMed ID: 27793693
    [Abstract] [Full Text] [Related]

  • 4. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.
    Siddiqui-Jain A, Bliesath J, Macalino D, Omori M, Huser N, Streiner N, Ho CB, Anderes K, Proffitt C, O'Brien SE, Lim JK, Von Hoff DD, Ryckman DM, Rice WG, Drygin D.
    Mol Cancer Ther; 2012 Apr 28; 11(4):994-1005. PubMed ID: 22267551
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
    Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B.
    Mol Cell Biochem; 2008 Sep 28; 316(1-2):163-7. PubMed ID: 18575815
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
    Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K.
    Cancer Res; 2010 Dec 15; 70(24):10288-98. PubMed ID: 21159648
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects.
    Zanin S, Sandre M, Cozza G, Ottaviani D, Marin O, Pinna LA, Ruzzene M.
    Biochim Biophys Acta; 2015 Oct 15; 1854(10 Pt B):1694-707. PubMed ID: 25936516
    [Abstract] [Full Text] [Related]

  • 12. CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome.
    Perera Y, Ramos Y, Padrón G, Caballero E, Guirola O, Caligiuri LG, Lorenzo N, Gottardo F, Farina HG, Filhol O, Cochet C, Perea SE.
    Mol Cell Biochem; 2020 Jul 15; 470(1-2):63-75. PubMed ID: 32405972
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P, Widło Ł, Skierka K, Krzyśko A, Koronkiewicz M, Cieśla JM, Cieśla J, Bretner M.
    Anticancer Res; 2019 Jul 15; 39(7):3531-3542. PubMed ID: 31262877
    [Abstract] [Full Text] [Related]

  • 14. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
    Gowda C, Sachdev M, Muthusami S, Kapadia M, Petrovic-Dovat L, Hartman M, Ding Y, Song C, Payne JL, Tan BH, Dovat S.
    Curr Pharm Des; 2017 Jul 15; 23(1):95-107. PubMed ID: 27719640
    [Abstract] [Full Text] [Related]

  • 15. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
    Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L, Gómez RE, Acevedo BE, Alonso DF, Perea SE.
    Mol Cancer Ther; 2009 May 15; 8(5):1189-96. PubMed ID: 19417160
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
    Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato G, Piazza F.
    J Hematol Oncol; 2013 Oct 12; 6():78. PubMed ID: 24283803
    [Abstract] [Full Text] [Related]

  • 17. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.
    Hung MS, Xu Z, Lin YC, Mao JH, Yang CT, Chang PJ, Jablons DM, You L.
    BMC Cancer; 2009 May 06; 9():135. PubMed ID: 19419583
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V, Borgo C, Cesaro L, Pinna LA, Donella-Deana A.
    Oncotarget; 2016 Apr 05; 7(14):18204-18. PubMed ID: 26919095
    [Abstract] [Full Text] [Related]

  • 19. Discovery of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine Derivatives as Highly Selective CK2 Inhibitors with Potent Cancer Cell Stemness Inhibition.
    Wang Y, Lv Z, Chen F, Wang X, Gou S.
    J Med Chem; 2021 Apr 22; 64(8):5082-5098. PubMed ID: 33834781
    [Abstract] [Full Text] [Related]

  • 20. CSNK2 in cancer: pathophysiology and translational applications.
    Strum SW, Gyenis L, Litchfield DW.
    Br J Cancer; 2022 Apr 22; 126(7):994-1003. PubMed ID: 34773100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.